Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 Pathway.
10.1007/s11655-024-3568-0
- Author:
Da-Lin SUN
1
;
Zi-Yi GUO
1
;
Wen-Yuan LIU
2
;
Lin ZHANG
1
;
Zi-Yuan ZHANG
2
;
Ya-Ling HU
2
;
Su-Fen LI
2
;
Ming-Yu ZHANG
1
;
Guang ZHANG
2
;
Jin-Jing WANG
1
;
Jing-Ai FANG
3
,
4
Author Information
1. The First College for Clinical Medicine, Shanxi Medical University, Taiyuan, 030001, China.
2. Department of Nephrology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
3. Department of Nephrology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China. jingaifang2017003@
4. com.
- Publication Type:Journal Article
- Keywords:
astragaloside IV;
diabetic nephropathy;
inositol-requiring enzyme 1α/nuclear factor kappa Bp65/NLR family pyrin domain containing 3 pathway;
podocyte
- MeSH:
Podocytes/metabolism*;
Animals;
Diabetic Nephropathies/metabolism*;
Saponins/therapeutic use*;
Triterpenes/therapeutic use*;
Signal Transduction/drug effects*;
NF-kappa B/metabolism*;
Protein Serine-Threonine Kinases/metabolism*;
Male;
Rats, Sprague-Dawley;
NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*;
Endoribonucleases/metabolism*;
Endoplasmic Reticulum Chaperone BiP;
Rats;
Diabetes Mellitus, Experimental/complications*;
Endoplasmic Reticulum/metabolism*;
Multienzyme Complexes
- From:
Chinese journal of integrative medicine
2025;31(5):422-433
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the effects of astragaloside IV (AS-IV) on podocyte injury of diabetic nephropathy (DN) and reveal its potential mechanism.
METHODS:In in vitro experiment, podocytes were divided into 4 groups, normal, high glucose (HG), inositol-requiring enzyme 1 (IRE-1) α activator (HG+thapsigargin 1 µmol/L), and IRE-1α inhibitor (HG+STF-083010, 20 µmol/L) groups. Additionally, podocytes were divided into 4 groups, including normal, HG, AS-IV (HG+AS-IV 20 µmol/L), and IRE-1α inhibitor (HG+STF-083010, 20 µmol/L) groups, respectively. After 24 h treatment, the morphology of podocytes and endoplasmic reticulum (ER) was observed by electron microscopy. The expressions of glucose-regulated protein 78 (GRP78) and IRE-1α were detected by cellular immunofluorescence. In in vivo experiment, DN rat model was established via a consecutive 3-day intraperitoneal streptozotocin (STZ) injections. A total of 40 rats were assigned into the normal, DN, AS-IV [AS-IV 40 mg/(kg·d)], and IRE-1α inhibitor [STF-083010, 10 mg/(kg·d)] groups (n=10), respectively. The general condition, 24-h urine volume, random blood glucose, urinary protein excretion rate (UAER), urea nitrogen (BUN), and serum creatinine (SCr) levels of rats were measured after 8 weeks of intervention. Pathological changes in the renal tissue were observed by hematoxylin and eosin (HE) staining. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to detect the expressions of GRP78, IRE-1α, nuclear factor kappa Bp65 (NF-κBp65), interleukin (IL)-1β, NLR family pyrin domain containing 3 (NLRP3), caspase-1, gasdermin D-N (GSDMD-N), and nephrin at the mRNA and protein levels in vivo and in vitro, respectively.
RESULTS:Cytoplasmic vacuolation and ER swelling were observed in the HG and IRE-1α activator groups. Podocyte morphology and ER expansion were improved in AS-IV and IRE-1α inhibitor groups compared with HG group. Cellular immunofluorescence showed that compared with the normal group, the fluorescence intensity of GRP78 and IRE-1α in the HG and IRE-1α activator groups were significantly increased whereas decreased in AS-IV and IRE-1α inhibitor groups (P<0.05). Compared with the normal group, the mRNA and protein expressions of GRP78, IRE-1α, NF-κ Bp65, IL-1β, NLRP3, caspase-1 and GSDMD-N in the HG group was increased (P<0.05). Compared with HG group, the expression of above indices was decreased in the AS-IV and IRE-1α inhibitor groups, and the expression in the IRE-1α activator group was increased (P<0.05). The expression of nephrin was decreased in the HG group, and increased in AS-IV and IRE-1α inhibitor groups (P<0.05). The in vivo experiment results revealed that compared to the normal group, the levels of blood glucose, triglyceride, total cholesterol, BUN, blood creatinine and urinary protein in the DN group were higher (P<0.05). Compared with DN group, the above indices in AS-IV and IRE-1α inhibitor groups were decreased (P<0.05). HE staining revealed glomerular hypertrophy, mesangial widening and mesangial cell proliferation in the renal tissue of the DN group. Compared with the DN group, the above pathological changes in renal tissue of AS-IV and IRE-1α inhibitor groups were alleviated. Quantitative RT-PCR and Western blot results of GRP78, IRE-1α, NF-κ Bp65, IL-1β, NLRP3, caspase-1 and GSDMD-N were consistent with immunofluorescence analysis.
CONCLUSION:AS-IV could reduce ERS and inflammation, improve podocyte pyroptosis, thus exerting a podocyte-protective effect in DN, through regulating IRE-1α/NF-κ B/NLRP3 signaling pathway.
